U.S. court upholds patent for Novartis MS drug Gilenya

U.S. court upholds patent for Novartis MS drug Gilenya

Source: 
Reuters
snippet: 

A U.S. district court upheld the validity of a patent for Swiss drugmaker Novartis’ top-selling multiple sclerosis (MS) drug Gilenya, helping Novartis protect its blockbuster MS treatment from U.S. competition.